Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

21. Dezember 2023 07:30 ET | Quelle: Arch Biopartners

Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

TORONTO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval in Turkey from the Kocaeli...
04. Mai 2021 07:00 ET | Quelle: Arch Biopartners

Arch Biopartners Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19

TORONTO, May 04, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
30. März 2021 07:57 ET | Quelle: Arch Biopartners

Turkish Ministry of Health Approves Increase in Patient Recruitment into the Phase II Trial for LSALT Peptide

TORONTO, March 30, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval from the Turkish Ministry...
16. März 2021 08:33 ET | Quelle: Arch Biopartners

Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Peptide

TORONTO, March 16, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for...
21. August 2020 08:00 ET | Quelle: Arch Biopartners

Arch Biopartners Obtains DTC Eligibility for its Common Shares on OTCQB

TORONTO, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced it has obtained eligibility with The Depository Trust...
07. August 2020 11:34 ET | Quelle: Arch Biopartners

Arch Biopartners to Hold LSALT Peptide Webinar and Q&A Session August 18, 2020 at 11am EST

TORONTO, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it will host a webinar on August 18, 2020 at...
04. März 2020 09:56 ET | Quelle: Arch Biopartners

Arch Biopartners Expands Dosing in Phase I Trial for Metablok to Increase Dose Range for Future Phase II Studies

TORONTO, March 04, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it is expanding the dose range of Metablok...
04. Dezember 2019 08:46 ET | Quelle: Arch Biopartners

Arch Biopartners Announces Issuance of U.S. Patent for Dipeptidase-1 Inhibitor Drug for Use in Acute Kidney Injury

TORONTO, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...